Page last updated: 2024-09-04

irofulven and Hematologic Diseases

irofulven has been researched along with Hematologic Diseases in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Blessing, JA; Pearl, ML; Rose, PG; Schilder, RJ1
Baker, SD; Britten, CD; Clark, GM; Drengler, R; Eckhardt, SG; Felton, S; Hammond, LA; Hidalgo, M; Kuhn, JG; MacDonald, JR; Moczygemba, J; Rowinsky, EK; Siu, L; Smith, C; Smith, SL; Villalona-Calero, MA; Von Hoff, DD; Weitman, S1

Trials

1 trial(s) available for irofulven and Hematologic Diseases

ArticleYear
Evaluation of irofulven (MGI-114) in the treatment of recurrent or persistent endometrial carcinoma: A phase II study of the Gynecologic Oncology Group.
    Investigational new drugs, 2004, Volume: 22, Issue:3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dose-Response Relationship, Drug; Endometrial Neoplasms; Female; Hematologic Diseases; Humans; Middle Aged; Nausea; Neoplasm Recurrence, Local; Sesquiterpenes; Treatment Outcome; Vomiting

2004

Other Studies

1 other study(ies) available for irofulven and Hematologic Diseases

ArticleYear
Phase I and pharmacokinetic study of irofulven, a novel mushroom-derived cytotoxin, administered for five consecutive days every four weeks in patients with advanced solid malignancies.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Dec-15, Volume: 18, Issue:24

    Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Drug Administration Schedule; Female; Hematologic Diseases; Humans; Kidney Diseases; Male; Middle Aged; Nausea; Neoplasms; Sesquiterpenes; Vomiting

2000